Mike Foote

GI medical oncologist @MSKCancerCenter | Translational Scientist in @ldiaz1971 lab

[Mike Foote @MikeFooteMD]

New in @NEJM and #AACR2025: Our Early-stage MMR-d neoadj I/O trial (led by @AndreaCercek & Luis Diaz)
•100 % cCR in 49 rectal pts
•65 % cCR across 10 other cancers (n=54)
•Safe + all non-CR/recurs salvaged.
=Use IO in NA for MMR-d tumors!

https://t.co/p6z3Q90ZTw

[𝐉𝐨𝐡𝐧-𝐖𝐢𝐥𝐥𝐢𝐚𝐦 𝐒𝐢𝐝𝐡𝐨𝐦, 𝐌𝐃, 𝐏𝐡𝐃 @John_Will_I_Am]

After almost 2 years of work, I'm beyond thrilled to share TESSERA 🎉

🧬 A foundation model for the cancer genome.

One genomic fingerprint →
🩺 Diagnosis
📈 Prognosis
🧪 Prediction

🚀 Preprint LIVE → https://t.co/BK2iZMbj8C

#CancerGenomics #FoundationModels #AIinMedicine

[Karuna Ganesh @KarunaMDPhD]

We are thrilled to share our latest work out today @Dev_Cell! Appendiceal adenocarcinoma (AC) is a rare, aggressive cancer that frequently spreads to the peritoneum. Until now, lack of robust preclinical models has severely limited drug discovery. https://t.co/8rPe1G87CZ🧵👇 🔗

[Mike Foote @MikeFooteMD]

@jpshen_md @GIMedOnc @fireflyann @GarridoLagunaMD Agree! Spots will be tough to get as per usual for a KRAS study but we will try our best to get folks on!

[Mike Foote @MikeFooteMD]

@CentralParkWMD @MarcHilmi And @dbittermanmd !!!

[Mike Foote @MikeFooteMD]

RT @MSKCancerCenter: New from #AACR26: A small clinical trial (8-person) at MSK is showing promise for people with early-stage #rectalcance…

[Mike Foote @MikeFooteMD]

RT @MSKCancerCenter: Recap of #AACR26 session with gastrointestinal medical oncologist Dr. Michael Foote.

[Mike Foote @MikeFooteMD]

@acpmpresearch @mskcc Thank you so much to the ACPMP and supporters for this great honor! We can’t wait to get started on finding new treatments for our patients.

[Appendix Cancer PMP Research Foundation @acpmpresearch]

We are proud to announce @MikeFooteMD of @MSKCC as the first-ever recipient of our $150K ACPMP Changemaker Research Grant for his research project, “Targeting the Surface Proteome of Appendiceal Cancer Peritoneal Metastasis.”

This research is made possible by our donors!🎗️

[Nicholas Hornstein @GIMedOnc]

Big day for a rare disease 🎉🧬

The new NCCN Guidelines for Appendiceal Cancer just dropped — and they’re fantastic. For the first time, this rare and often misunderstood disease finally gets its own dedicated guidance, instead of the old “just follow colorectal cancer” footnote.

📘 Clear frameworks for diagnosis, staging, and management
🔍 Recognition that appendiceal primaries are biologically distinct
💡 Emphasis on multidisciplinary care and the need for more trials
Only downside? @jpshen_md and Michael Foote — two of the biggest names in this space — weren’t listed as contributors.
Still, a huge step forward for patients and clinicians who’ve long been navigating in the dark. The field is finally getting the structure it deserves.

https://t.co/10MLAkG1Mi

@OncoAlert @TheGutOncLab #GIOncology #AppendicealCancer @acpmpresearch

[Mike Foote @MikeFooteMD]

Father and son enjoying #ESMO25 in Berlin!!

[MSK Department of Medicine @MSK_DeptOfMed]

Exciting research is ahead at #ESMO25! Tomorrow, @MikeFooteMD will present interim safety and efficacy data of a phase 1/1b study of an investigational drug for people with advanced solid tumors. @MSKCancerCenter @myESMO

Learn more: https://t.co/6ZhqtdZfN0

[Dra. María Natalia Gandur Quiroga @nataliagandur]

🌟Therapeutic Targeting of MMR-Deficient Cancers🌟
🖋️ Paul Johannet, Benoit Rousseau, Carol Aghajanian,
@MikeFooteMD @MSKCancerCenter @ldiaz1971
@NatureRevCancer @Nature @OncoAlert
“MMRd tumors: an immunogenic paradox — vulnerable yet resilient”
🔵 Immune-checkpoint inhibitors (ICIs) provide durable responses in many MMRd/MSI-H tumors, regardless of tumor origin
🔵 These tumors harbor frameshift mutations → neoantigens → high immunogenicity
🔵 Strong TILs, checkpoint expression & molecular profile contribute to ICI sensitivity
🔵 Yet, not all MMRd tumors respond and many acquire resistance
🔵 Review explores biology, genomic sequelae, epidemiology & therapeutic strategies
🔵 Highlights emerging biomarkers, resistance mechanisms & future directions

💡 A must-read synthesis connecting tumor genomics with immunotherapy impact

#MSI #MMRd #Immunotherapy #ICIs #CancerBiomarkers #OncoImmunology #TumorMicroenvironment #DNARepair #Oncology #CancerResearch #OncoTwitter
https://t.co/pGI7XquhCS

[Mike Foote @MikeFooteMD]

Very excited about our work with 60+ collaborators across the world to define algorithms for management of patients with peritoneal disease! https://t.co/CppEQ8gbWg

[Dr. Cathy Eng @CathyEngMD]

Part 1: Consensus guideline for the management of patients with appendiceal tumors: Appendiceal tumors without peritoneal involvement - Godfrey - 2025 - Cancer - Wiley Online Library https://t.co/dYjTLYSeSa @DeepaMagge @kturaga @ArdamanShergil1 @MikeFooteMD @JournalCancer @appendix #cancer #raretumors

[Dr. Cathy Eng @CathyEngMD]

@SchultzKurt @MikeWach_MD @ardamanshergill @MikeFooteMD and many others! @YaleMed @MoffittNews @UofC @MSKCancerCenter #cancer #peritoneum #colorectalcancer #cancerreserach

[Mike Foote @MikeFooteMD]

So excited for Benoit Rousseau’s paper in Cancer Cell describing mutagenic chemo combinations to make cold tumors hot!

https://t.co/8WOXtOarWY

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

🚨 New research from @ASCO: A clinical trial led by @YJanjigianMD, Chief of Gastrointestinal Medical Oncology at MSK, has demonstrated a powerful new approach to help prevent cancer from coming back after treatment for #stomachcancer and #cancer of the lower portion of the #esophagus and gastroesophageal junction (#GEJ).

“For gastroesophageal cancer patients to go through surgery and chemo, it’s devastating to have a recurrence of the cancer,” says Dr. Janjigian. “This trial shows that adding immunotherapy to chemo before and after surgery can dramatically improve the chance that cancer won’t return.”

Learn more about how these results offer new hope to people facing this diagnosis, which is the fifth most common cancer worldwide: https://t.co/C4hzxgoabS

#ASCO25

[Andrea Cercek @AndreaCercek]

Congratulations to our team. Next chapter in Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine https://t.co/HSiWCtCiSz

[Luis Diaz @ldiaz1971]

New paper from our team at @MSKCancerCenter. Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine https://t.co/H9bnB54BFf

[NEJM @NEJM]

Presented at #AACR25:

Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: https://t.co/o5tjgLnXm6 

@AACR

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

An approach pioneered at MSK that caused #rectalcancer tumors with a specific genetic mutation to disappear in 100% of clinical trial participants has been expanded to treat other types of cancer, including stomach (gastric), colon, esophageal, urothelial, and others.

Gastrointestinal oncologist @AndreaCercek presented the results from a larger clinical trial at #AACR25. The new results saw 80% of patients with several types of cancer successfully treated with only #immunotherapy.

“This is very exciting and shows that a broad range of tumors with this genetic mutation called MMRd can be treated with immunotherapy replacing surgery and radiation, giving patients better quality of life." Learn more: https://t.co/RoAJIHtizP #AACR25 @AACR